Israel Englander Humanigen, Inc Transaction History

Millennium Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.12 - $0.23 $12,760 - $24,458	-106,341 Reduced 86.22%	16,989 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $29,370 - $65,268	-326,344 Reduced 72.57%	123,330 $15,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $2,202 - $44,336	-14,681 Reduced 3.16%	449,674 $81,000
Q2 2022 Aug 15, 2022	BUY	$1.76 - $3.33 $817,264 - $1.55 Million	464,355 New	464,355 $822,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $1.6 Million - $3.52 Million	-886,286 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $3.1 Million - $6.96 Million	847,109 Added 2162.26%	886,286 $3.3 Million
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $168,115 - $505,480	-28,350 Reduced 41.98%	39,177 $232,000
Q2 2021 Aug 16, 2021	SELL	$13.54 - $22.74 $8.69 Million - $14.6 Million	-641,612 Reduced 90.48%	67,527 $1.17 Million
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $8.43 Million - $15.6 Million	653,367 Added 1171.5%	709,139 $13.5 Million
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $139,937 - $380,306	17,558 Added 45.95%	55,772 $976,000
Q3 2020 Nov 16, 2020	BUY	$8.0 - $28.5 $305,712 - $1.09 Million	38,214 New	38,214 $407,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.